Mela Sciences (NSDQ:MELA) added five new members to its board of directors this month, looking to tap their expertise in advance of a planned launch in the U.S. and Germany in the first quarter of 2012.
The Irvington, N.Y.-based company named the new directors on the heels of two regulatory wins granting its flagship skin cancer detection device MelaFind market access in the U.S. and Europe.
Mela won FDA clearance early last month after more than two years in regulatory limbo, and landed CE Mark approval in the European Union in September.
"The FDA approval of MelaFind marks the most important achievement in the company’s history and represents a significant advance for the millions of Americans who are at risk of developing this terrible disease," president & CEO Dr. Joseph Gulfo said in November.
Mela’s new board members come in to replace outgoing directors Sidney Braginsky and George Chryssis, both members since 2001, as well as Breaux Castleman, member since 2003, and Gerald Wagner, director since 2005.
Dr. Gulfo added, "Having achieved FDA and CE Mark approvals in 2011, it is with bittersweet emotion that we effect these changes to our Board, saying goodbye to directors who have served multiple tours in our fight to win the product approvals," president & CEO Joseph Gulfo said in prepared remarks. "We sincerely thank Messrs. Braginsky, Castleman, Chryssis and Dr. Wagner for their excellent contributions, without which we could not have succeeded, and we wish them well."
Mela’s new directors are:
- Robert Coradini, Johnson & Johnson (NYSE:JNJ) veteran.
- Mark Fabiani, former special counsel to President Clinton.
- John Goddard, former CFO for AstraZeneca U.S.
- James Noble, CEO of Immunocore
- David Stone, founder and managing director of Liberty Tree Advisors, LLC
"With FDA and CE Mark approval of our breakthrough product, MelaFind, we are now a commercial-stage company, and we look to the expertise of our new directors in the fields of international sales and marketing, investor and public relations, accounting, business development, and strategic planning as we prepare for our first quarter 2012 product launches in the US and Germany," said Gulfo added.
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Intrinsic Therapeutics names new president & CEO
Woburn, Mass.-based spinal therapies maker Intrinsic Therapeutics named Cary Hagan president & CEO. Read more
DJO Global announces COO departure
DJO Global Inc., a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, announced the resignation of Luke Faulstick, executive VP and COO, who will depart in early February, 2012. Read more
Competitive Technologies gets new board chairman
Competitive Technologies Inc. (PINK:CTTC) announced that Rustin R. Howard, who has served as a director of CTTC since October of 2007, has been elected chairman of its board of directors, effective immediately. Read more